SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention after a recent rebound that traders say held its gains, with bullish technical setups and positioning ahead of earnings. The upbeat view contrasts with concerns that high rates and a sluggish housing market could continue to weigh on renovation demand.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sharp rally to fresh multi-year highs is drawing attention, with traders citing rotation into defensive, dividend-paying pharma stocks and positioning ahead of the quarterly report. Bulls see a technical breakout and pipeline momentum, while skeptics warn the move may meet resistance and point to patent-expiration and growth concerns.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,397.34014094 USD and is up 0.28 over the last 24 hours. It is currently trading on 12773 active market(s) with $12,152,377,915.37 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin is drawing attention amid concerns over Binances reported major hack and paused withdrawals, with traders debating whether damaged exchange trust could trigger further selling. Others argue the market is absorbing the shock and point to Binances reported reimbursement progress and planned withdrawal reopening as reasons for optimism.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on expected Q3 results and the Phase 3 QUILT-2.005 topline for ANKTIVA plus BCG in BCG-naive bladder cancer; the trial is database-locked, with a supplemental filing planned if results support it. Bullish traders see the readout and ANKTIVAs expanded bladder-cancer label as growth catalysts, while others question commercial uptake and point to competition, short-selling, and broader market weakness to explain the volatility.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention as traders use the leveraged inverse Nasdaq ETF to hedge or bet on further weakness in tech, citing concerns about AI spending and valuations alongside recent tech-led selling. The community is divided: some expect more downside, while others warn that rumors of a U.S.Iran deal and a possible market rebound could reverse gains in the short ETF.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow is being discussed amid volatile, uneven trading across major indexes, with traders watching Fed policy and rising Treasury yields as pressures on equities. Some see relative strength in the Dow as money rotates away from tech, while others warn that inflation, oil-market risks and weakening momentum could deepen a selloff.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Discussion centers on BioCrysts upcoming quarterly results and whether continued ORLADEYO growth can support the stock despite its weak performance. Traders are also looking ahead to Navenibart and Netherton data, while debating managements acquisition strategy and expressing frustration over dilution and limited shareholder returns; buyout talk remains speculative.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results and outlook are drawing attention, with traders highlighting stronger streaming profitability and resilient theme-park performance. The reaction is mixed: some see support for a turnaround, while others point to the stocks persistent range-bound price action and difficulty holding gains.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention ahead of its upcoming earnings report, with traders watching whether guidance holds and how management addresses pressure on the pharmacy benefit management business. Some see the recent pullback as a potential technical rebound setup, while others remain cautious after the stocks recent selling.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

A sharp volatility spike has lifted UVIX, drawing traders seeking a hedge against a broader market pullback. The community is split between expecting volatility to persistciting concerns about oil, interest rates and geopolitical risksand warning that UVIX can quickly lose value as volatility fades and its leveraged futures exposure decays.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial

Equity

Galectin plans to submit the final trial protocol to the FDA in the third quarter of 2026.


Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FY2026 Earnings Estimate for GALT Issued By HC Wainwright

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Research analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Galectin Therapeutics in a note issued to investors on...

What is HC Wainwright's Estimate for GALT Q1 Earnings?

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Galectin Therapeutics in a note issued to investors on...

Galectin Therapeutics (NASDAQ:GALT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02...

Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 27.0% in March

Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,567,660 shares, an increase of 27.0% from the February 26th total of 5,169,383 shares. Currently, 21.5% of the company's...

Galectin Therapeutics (GALT) Projected to Post Earnings on Monday

Galectin Therapeutics (NASDAQ:GALT) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-galectin-therapeutics-inc-stock...

Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps

Galectin Therapeutics (NASDAQ:GALT) hosted a virtual key opinion leader (KOL) event to discuss belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>CEO Joel Lewis said the agreement provides “important clarity” and renewed confidence as the company advances the program while exploring strategic partnerships.</li><li>Belapectin is an investigational drug that targets galectin-3 protein to reduce liver inflammation and scarring.</li><li>On Stocktwits, retail sentiment around GALT jumped from ‘bearish’ to ‘bullish’ over the past 24 hours.</li></ul>Shares of Galectin Therapeutics Inc. (GALT) jumped 22% on Tuesday after the company said that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a planned late-stage trial for belapectin in patients with MASH cirrhosis and portal hypertension, giving the company a clearer roadmap to potential marketing approval.The stock is on track to clock its best day since June 2025, if the gains hold.<h2 class="st-heading-2">What GALT’s Late-stage Trial Will Look Like</h2>MASH cirrhosis is advanced liver scarring from fatty liver disease, while portal hypertension is dangerously high blood pressure in the liver’s veins. Together, they sharply raise the risk of life-threatening bleeding from enlarged veins called varices.Galectin’s trial will evaluate a single 2 mg dose of belapectin in patients with these conditions. The main goal will be to prevent esophageal varices.The study will use the same centralized, blinded endoscopy review process successfully employed in an earlier trial and is expected to be similar in size. Galectin plans to submit the&nbsp; final protocol to the FDA in the third quarter of 2026.CEO Joel Lewis said the agreement provides “important clarity” and renewed confidence as the company advances the program while exploring strategic partnerships.<h2 class="st-heading-2">Background And Next Steps</h2>Belapectin is an investigational drug that targets galectin-3 protein to reduce liver inflammation and scarring. Data from an earlier trial showed it reduced the development of varices in high-risk MASH cirrhosis patients.Galectin is now preparing for the late-stage study and seeking partnerships to support development. The company emphasized that approval in this population would follow the traditional full-approval pathway rather than accelerated approval.<h2 class="st-heading-2">How Did GALT Retail Traders React?</h2>On Stocktwits, retail sentiment around GALT jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism for a partnership announcement soon.<stembedurl>https://www.stocktwits.com/th3_fail_k1ng/message/657170477</stembedurl>Yet another voiced optimism on the market potential of belapectin.<stembedurl>https://www.stocktwits.com/JBRUN/message/657187488</stembedurl><a href="https://stocktwits.com/symbol/GALT">GALT stock</a> has fallen 11% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spcx-bond-offering-attracts-3x-more-demand-outstanding-long-term-debt/cZKwBU1R7at">SPCX’s Inaugural Bond Offering Attracts Over 3x More Demand Than Its Outstanding Long-Term Debt: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Galectin Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Galectin plans to submit the final trial protocol to the FDA in the third quarter of 2026.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.32
Prev Close	$3.52
Open	$3.52
Dividend Yield	0.00%
50-Day Moving Average	$3.81
Beta	0.56
Avg. Volume	321,549.08
PE Ratio	-7.73

52-Week High	$7.13
52-Week Low	$2.03
Market Capitalization	$334.82M
EPS (Annual)	-$0.4847
Price to Book	-1.58
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GALT Fundamentals